Marietta Wealth Management LLC cut its position in Becton, Dickinson and Company (NYSE:BDX) by 4.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,577 shares of the medical instruments supplier’s stock after selling 154 shares during the quarter. Marietta Wealth Management LLC’s holdings in Becton, Dickinson and were worth $698,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Almanack Investment Partners LLC. purchased a new position in shares of Becton, Dickinson and in the first quarter valued at $105,000. Parkside Financial Bank & Trust boosted its stake in Becton, Dickinson and by 1.4% during the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 9 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 240 shares during the last quarter. QCI Asset Management Inc. NY boosted its stake in Becton, Dickinson and by 9.2% during the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after acquiring an additional 60 shares during the last quarter. Finally, Financial Architects Inc boosted its stake in Becton, Dickinson and by 8.0% during the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after acquiring an additional 54 shares during the last quarter. Institutional investors and hedge funds own 87.12% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 201.43 on Monday. The company has a 50 day moving average of $197.13 and a 200-day moving average of $193.13. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The firm has a market cap of $45.84 billion, a PE ratio of 58.33 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same quarter in the previous year, the company earned $2.35 EPS. The firm’s revenue for the quarter was down 5.1% compared to the same quarter last year. Equities research analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were paid a $0.73 dividend. The ex-dividend date was Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.45%. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/10/16/marietta-wealth-management-llc-has-698000-stake-in-becton-dickinson-and-company-bdx.html.

In related news, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the transaction, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock worth $15,242,688 in the last 90 days. 1.40% of the stock is owned by corporate insiders.

BDX has been the topic of a number of research analyst reports. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their price objective for the company from $210.00 to $180.00 in a research note on Friday, June 30th. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research note on Monday, July 17th. Finally, Wells Fargo & Company initiated coverage on shares of Becton, Dickinson and in a research note on Friday, September 22nd. They set an “outperform” rating and a $225.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $200.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.